Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 10

1.

Computed Tomography Findings Associated With 30-Day Mortality in Patients With Malignant Superior Vena Cava Syndrome.

Tamir S, Friehmann T, Ratzon R, Livneh N, Spectre G, Atar E, Grubstien A, Raanani P, Brenner B, Leader A.

J Comput Assist Tomogr. 2019 Nov/Dec;43(6):912-918. doi: 10.1097/RCT.0000000000000934.

PMID:
31738208
2.

Anthracycline-Induced Cardiotoxicity in Acute Myeloid Leukemia Patients Who Undergo Allogeneic Hematopoietic Stem Cell Transplantation.

Pasvolsky O, Morelli O, Rozovski U, Vaturi M, Wolach O, Amitai I, Vaxman I, Ratzon R, Yeshurun M, Kornowski R, Iakobishvilli Z, Raanani P.

Clin Lymphoma Myeloma Leuk. 2019 Jul;19(7):e343-e348. doi: 10.1016/j.clml.2019.03.007. Epub 2019 Mar 11.

PMID:
30948329
3.

Thrombosis, anticoagulation and outcomes in malignant superior vena cava syndrome.

Ratzon R, Tamir S, Friehmann T, Livneh N, Dudnik E, Rozental A, Hamburger-Avnery O, Pereg D, Derazne E, Brenner B, Raanani P, Ten Cate H, Spectre G, Leader A.

J Thromb Thrombolysis. 2019 Jan;47(1):121-128. doi: 10.1007/s11239-018-1747-6.

PMID:
30255420
4.

Real-life Experience With Ponatinib in Chronic Myeloid Leukemia: A Multicenter Observational Study.

Shacham-Abulafia A, Raanani P, Lavie D, Volchek Y, Ram R, Helman I, Shargian L, Gourevitch A, Chubar E, Ratzon R, Rozovski U.

Clin Lymphoma Myeloma Leuk. 2018 Jul;18(7):e295-e301. doi: 10.1016/j.clml.2018.05.002. Epub 2018 May 7.

PMID:
29773429
5.

Impact of an extended challenge on the effectiveness of ╬▓-lactam hypersensitivity investigation.

Ratzon R, Reshef A, Efrati O, Deutch M, Forschmidt R, Cukierman-Yaffe T, Kenett R, Kidon MI.

Ann Allergy Asthma Immunol. 2016 Apr;116(4):329-33. doi: 10.1016/j.anai.2016.01.018. Epub 2016 Feb 26.

PMID:
26922211
6.

Fetal exposure to nonsteroidal anti-inflammatory drugs and spontaneous abortions.

Daniel S, Koren G, Lunenfeld E, Bilenko N, Ratzon R, Levy A.

CMAJ. 2014 Mar 18;186(5):E177-82. doi: 10.1503/cmaj.130605. Epub 2014 Feb 3.

7.

Effect of interpregnancy interval on outcomes of pregnancy after recurrent pregnancy loss.

Bentolila Y, Ratzon R, Shoham-Vardi I, Serjienko R, Mazor M, Bashiri A.

J Matern Fetal Neonatal Med. 2013 Sep;26(14):1459-64. doi: 10.3109/14767058.2013.784264. Epub 2013 May 7.

PMID:
23488821
8.

Primary vs. secondary recurrent pregnancy loss--epidemiological characteristics, etiology, and next pregnancy outcome.

Shapira E, Ratzon R, Shoham-Vardi I, Serjienko R, Mazor M, Bashiri A.

J Perinat Med. 2012 Feb 29;40(4):389-96. doi: 10.1515/jpm-2011-0315.

PMID:
22752770
9.

Two vs. three or more primary recurrent pregnancy losses--are there any differences in epidemiologic characteristics and index pregnancy outcome?

Bashiri A, Ratzon R, Amar S, Serjienko R, Mazor M, Shoham-Vardi I.

J Perinat Med. 2012 Feb 16;40(4):365-71. doi: 10.1515/jpm-2011-0295.

PMID:
22752766
10.

The role of prenatal care in recurrent preterm birth.

Ratzon R, Sheiner E, Shoham-Vardi I.

Eur J Obstet Gynecol Reprod Biol. 2011 Jan;154(1):40-4. doi: 10.1016/j.ejogrb.2010.08.011. Epub 2010 Sep 24.

PMID:
20869804

Supplemental Content

Loading ...
Support Center